Peptide library

DSIP peptide
(emideltide)

DSIP, delta sleep-inducing peptide, is a nine-amino-acid peptide described from rabbits in 1977. Where the name comes from, how it has been studied, what FDA staff concluded, and where it stands in November 2026.

Short answerCompound research · 6 min read · Updated 18 Nov 2026

DSIP, delta sleep-inducing peptide, also listed as emideltide, is a nine-amino-acid peptide described from rabbits in 1977. Its name comes from animal EEG studies, not from findings in people. FDA staff called its small human sleep studies “inconclusive and at best preliminary” and found no safety data for the route nominators proposed. It is not FDA-approved.

Key takeaways

  • DSIP is the nine-amino-acid peptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; emideltide is its international nonproprietary name.
  • Its name comes from 1977 rabbit studies that measured delta waves on the EEG; a 2006 review called the idea of DSIP as a sleep factor “extremely poorly documented and still weak”.
  • The human studies FDA staff describe were small, published between 1981 and 1998, and FDA staff called the insomnia evidence “inconclusive and at best preliminary”.
  • FDA staff recommended against adding it to the 503A bulks list; by press reports, the July 2026 advisory committee voted 7 to 6 against, with one abstention.
  • It is not FDA-approved, is not in HHS’s October 2026 compounding policy, and is not named on WADA’s 2026 or 2027 List.

01DSIP at a glance

The short version, dated 18 November 2026. Every line is sourced at the end of the page.

QuestionDSIP (emideltide)
What it isA peptide of nine amino acids, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (C35H48N10O15, 848.8 g/mol), characterised from rabbits in 1977.
Other namesDelta sleep-inducing peptide; emideltide, its international nonproprietary name (INN).
Evidence tierT3 for the EEG findings in rabbits, rats and cats. T2 for people: the placebo-controlled studies FDA staff describe in detail had 6 to 16 people each.
Human studies209 people, for 1 to 15 days each, in the studies FDA staff found, from 1981 on. None on ClinicalTrials.gov (searched 18 Nov 2026).
United StatesNot FDA-approved. Formerly in compounding Category 2; both nominations withdrawn in April 2026 (FDA docket, posted 14 Apr 2026; FDA list, current 22 Apr 2026). FDA staff recommended against the 503A bulks list; by press reports, the July 2026 committee voted 7 to 6 against. Not in HHS’s October 2026 policy.
United Kingdom and EuropeNo result on the UK emc database (18 Nov 2026); not a registered drug in any country FDA staff searched.
AustraliaNot named in the Poisons Standard October 2026 (text searched 18 Nov 2026).
WADANot named on the 2026 or 2027 List; check with your anti-doping body.

02What is DSIP, and where does its name come from?

DSIP is a short peptide of nine amino acids. In 1977, researchers in Basel described it from rabbits and reported that, infused into the brain, it increased delta waves and spindles on the EEG, the electrical patterns of deep non-REM sleep, in a study of 58 rabbits including controls. The name comes from that finding (T3). It is not a result in people.

Later animal work did not settle it. FDA staff summarise rabbit, rat and cat studies that recorded more delta activity or longer non-REM sleep, and describe the effect in animals as “conserved across species” (T3). They also note inconsistent findings: a 1980 rat study found no increase in delta waves, and cat and rat studies disagree on which sleep stages change. A 2006 review was more sceptical: the link between DSIP and sleep “has never been further characterized”, partly because no DSIP gene, precursor protein or receptor had been isolated, and the idea of DSIP as a sleep factor is “extremely poorly documented and still weak”.

In rats, a drug that blocks opioid receptors prevented DSIP’s effect on sleep, although DSIP does not bind those receptors itself, FDA staff write: its effects appear to run partly through the opioid system.

FDA staff also found different salts and derivatives sold under the same name, and concluded that neither emideltide nor its acetate salt is “well-characterized”.

03How has DSIP been studied in people, and what did FDA staff conclude?

Small studies, most from the 1980s, reviewed by FDA staff in 2026 for three uses nominators proposed: chronic insomnia, narcolepsy and opioid withdrawal.

StudyPeopleDesignWhat the authors or FDA staff concluded
Schneider-Helmert et al., 19816 healthy volunteersDouble-blind, placebo-controlled crossoverFDA staff: the first-in-human pilot; sleep recordings and ratings
Schneider-Helmert and Schoenenberger, 19816 adults with chronic insomniaRandomised, double-blind, placebo-controlled crossoverFDA staff: results given mostly as p values, and unclear whether changes were clinically meaningful
Schneider-Helmert, 198714 adults with chronic insomniaDouble-blind; compared with healthy external controls, with no placebo armFDA staff: small sample and poor methodology limit interpretation
Monti et al., 19876 adults with severe chronic insomniaRandomised, double-blind, placebo-controlled crossoverFDA staff: no significant differences from baseline or placebo; the authors judged the changes “of little clinical significance”
Bes et al., 199216 adults with chronic insomniaDouble-blind, placebo-controlled, two parallel groupsThe authors: effects were weak and “not likely to be of major therapeutic benefit”
Dick et al., 1984; Backmund et al., 1998107 people in alcohol or opioid withdrawal; 7 in opioid withdrawalOpen-label, no comparison groupFDA staff: small, unblinded and uncontrolled
Schneider-Helmert, 19841 man with narcolepsyCase reportFDA staff: a single case limits interpretation

FDA staff’s verdict: studies authored by Schneider-Helmert reported improved sleep measures, while the two double-blind, placebo-controlled studies from other groups “did not reach the same conclusions”. They called the insomnia evidence “inconclusive and at best preliminary”, found insufficient evidence for all three uses, and found no study of the route the nominators proposed and no information on benefit with long-term use.

04What have regulators said about DSIP safety?

FDA staff found no safety data for the route nominators proposed and called DSIP’s safety “insufficiently characterized”. Both sides of their review:

What was reported. FAERS, FDA’s adverse-event database, held no reports for emideltide through 3 March 2024, and FDA staff found no published case reports. The insomnia studies reported no significant adverse effects. In a 1984 withdrawal study of 107 people, nine had minor, short-lived effects such as headache, nausea and vertigo, and three had serious adverse effects: two had a fall in blood pressure as treatment began, and one had repeated discomfort with sweating and nausea. One of these three, given it a second time, had “progressive hypotension”. FDA staff note that withdrawal symptoms make these reports hard to interpret.

What FDA staff found missing. FDA staff found no toxicity studies of repeated exposure, no reproductive studies and no two-year cancer studies in animals. A mouse study of Deltaran, a Russian product combining DSIP with glycine, cannot show that DSIP lacks cancer or genetic-damage potential, they wrote, partly because glycine, the other ingredient, has itself been reported to have anti-mutagenic and anti-cancer properties.

Two concerns. Because DSIP’s effects in animals involve the opioid system, FDA staff wrote that this “could lead to development of addiction”, and they found no study of its abuse potential. And as a nine-amino-acid peptide given by the route nominators proposed, emideltide “may pose a significant risk for immunogenicity”, an unwanted immune response. More: side effects, documented vs unknown.

05Is DSIP an approved medicine? Status by country

United States. DSIP is not an FDA-approved drug or a component of one. FDA’s compounding page lists “Emideltide (DSIP)” among substances previously in Category 2 whose nominations were withdrawn; the page is current as of 22 April 2026, and FDA’s docket posted the two nominators’ withdrawal letters on 14 April 2026. FDA staff, evaluating it on the agency’s own initiative, proposed not adding either form to the 503A bulks list. At the advisory committee meeting of 24 July 2026, by press reports, members voted 7 to 6 against adding emideltide, with one abstention; FDA had posted no minutes by 18 November 2026. DSIP is not among the six peptides in HHS’s October 2026 enforcement-discretion policy. Background: the July 2026 vote, the HHS policy, FDA’s categories.

United Kingdom and Europe. Searches of the emc database for emideltide and for DSIP returned no results on 18 November 2026. FDA staff found no monograph in the European, Japanese or International Pharmacopoeia, and no country among those they searched where emideltide is a registered drug. More: are peptides legal in the UK?

Australia. Emideltide is not named in the Poisons Standard October 2026, and we found no group entry that would cover it. More: are peptides legal in Australia?

Sport. DSIP is not named on WADA’s 2026 or 2027 Prohibited List. Class S0 prohibits at all times any substance not addressed elsewhere on the List “and with no current approval by any governmental regulatory health authority for human therapeutic use”. FDA staff found no country, among those they searched, where emideltide is a registered drug; anti-doping organisations decide how S0 applies. See peptides and anti-doping.

06What we don’t know about DSIP

  • Whether DSIP changes sleep in people. The placebo-controlled studies were small, disagreed with each other, and none is recent.
  • Whether the body uses DSIP as a sleep signal at all: its gene, precursor and receptor had not been isolated by 2006.
  • Its safety with repeated use or by the route nominators proposed, and its abuse potential. FDA staff found these unstudied.
  • What a vial sold as DSIP contains. The name is used for different salts and derivatives; only a lab report on that lot can show it: how to read a COA.

Related: the sleep research area and the epitalon guide.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: emideltide-related bulk drug substances (FDA evaluation dated 11 May 2026). Advisory committee briefing, 2026 (pp. 9–14, 20–23, 25–35, 38–56); read 18 Nov 2026. www.fda.gov/media/193344/download
  2. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  3. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda, voting questions, briefing documents; no minutes posted). Advisory committee calendar, content current 6 Aug 2026; read 18 Nov 2026. www.fda.gov/advisory-committees/advisory-committee-calendar/…
  4. American Med Spa Association. FDA advisory committee recommends adding six of seven peptides to compounding list. News report of the vote counts, 24 Jul 2026; read 18 Nov 2026. www.americanmedspa.org/news/fda-advisory-committee-recommend…
  5. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, Oct 2026. hhs.gov returned 403 on 18 Nov 2026; read on the Internet Archive capture of 15 Nov 2026, the newest capture of this URL. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  6. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A, 1977;74(3):1282–1286. PMID 265572. pubmed.ncbi.nlm.nih.gov/265572/
  7. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem, 2006;97(2):303–309. PMID 16539679. pubmed.ncbi.nlm.nih.gov/16539679/
  8. Human studies, abstracts read 18 Nov 2026: Schneider-Helmert D et al., Int J Clin Pharmacol Ther Toxicol 1981 (PMID 6895513); Schneider-Helmert D, Schoenenberger GA, Experientia 1981 (PMID 7028502); Monti JM et al., Int J Clin Pharmacol Res 1987 [double-blind crossover study in six adults with chronic insomnia] (PMID 3583493); Bes F et al., Neuropsychobiology 1992 (PMID 1299794). Other studies in the table are cited through FDA’s briefing. pubmed.ncbi.nlm.nih.gov/?term=6895513+OR+7028502+OR+3583493+…
  9. World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027), class S0. International Standard; both PDFs searched 18 Nov 2026. www.wada-ama.org/en/prohibited-list
  10. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation, commenced 1 Oct 2026; full text searched 18 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  11. Database searches run 18 Nov 2026: emc (“emideltide”, “DSIP”: no results); Drugs@FDA via openFDA (“emideltide”: no records); ClinicalTrials.gov, intervention “emideltide”, “DSIP” or “delta sleep-inducing peptide” (no study of DSIP); PubChem CID 68816 (synonyms, formula, weight). Registry and database queries. pubchem.ncbi.nlm.nih.gov/compound/68816
  12. U.S. Food and Drug Administration. Docket FDA-2015-N-3534: withdrawal letters from the two emideltide nominators (documents FDA-2015-N-3534-0484 and FDA-2015-N-3534-0485, cited in FDA’s briefing, footnote 3). Docket records, posted 14 Apr 2026; titles and posting dates read through the Regulations.gov API on 18 Nov 2026. www.regulations.gov/document/FDA-2015-N-3534-0484

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

What is DSIP peptide?

DSIP, delta sleep-inducing peptide, is a nine-amino-acid peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, described from rabbits in 1977. Its international nonproprietary name is emideltide.

Is there evidence that DSIP affects sleep in people?

Not reliable evidence. The name comes from rabbit EEG studies; in people, the small placebo-controlled studies disagreed, and FDA staff called the insomnia evidence “inconclusive and at best preliminary”.

Is DSIP FDA-approved?

No. FDA staff recommended against adding it to the list of substances pharmacies may compound with, and by press reports the July 2026 advisory committee voted 7 to 6 against. It is not in HHS’s October 2026 compounding policy.

What is known about DSIP side effects?

FDA staff found no adverse-event reports in FAERS through March 2024 and no published case reports. A 1984 withdrawal study reported minor effects such as headache and nausea and three serious events, including low blood pressure. FDA staff call its safety “insufficiently characterized” and wrote that, by the route nominators proposed, it “may pose a significant risk for immunogenicity”.

Is DSIP prohibited in sport?

It is not named on WADA’s 2026 or 2027 List. WADA’s class S0 prohibits at all times substances with no current government approval for human therapeutic use; FDA staff found no country, among those they searched, where it is a registered drug, and anti-doping organisations decide how S0 applies.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page